Document is current
Any future updates will be listed below
-
Authors
van Alderwerelt van Rosenburgh, Iris K.
Lu, David M. https://orcid.org/0000-0003-1739-6649
Grant, Michael J.
Stayrook, Steven E. https://orcid.org/0000-0002-1677-8293
Phadke, Manali https://orcid.org/0000-0003-2268-5963
Walther, Zenta
Goldberg, Sarah B.
Politi, Katerina
Lemmon, Mark A. https://orcid.org/0000-0002-3379-5319
Ashtekar, Kumar D. https://orcid.org/0000-0001-8264-6558
Tsutsui, Yuko https://orcid.org/0000-0002-3286-3295
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50-CA196530, T32-CA233414, P50-CA196530, P50-CA196530, P30-CA016359, R01-CA198164, P50-CA196530, R03-CA259881)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Conquer Cancer Foundation (2021YIA-0474838505)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Arnold and Mabel Beckman Foundation (17-001959)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 31 May 2022
Accepted: 19 October 2022
First Online: 10 November 2022
Competing interests
: S.B.G. has received research funding from AstraZeneca, Boehringer Ingelheim, and Mirati. S.B.G. is also a consulting/advisory board member for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Amgen, Blueprint Medicine, Sanofi Genzyme, Daiichi-Sankyo, Regeneron, Takeda, and Janssen. K.P. has received research funding from AstraZeneca, D2G Oncology, Roche/Genentech and Boehringer Ingelheim; and honoraria from Halda, Janssen, and AstraZeneca. K.P. is co-inventor on a patent for EGFR T790M mutation testing (WO2006086777A3) issued, licensed, from Memorial Sloan Kettering Cancer Center, for which she receives royalties. All remaining authors report no competing interests.
